Taysha Gene Therapies Inc (TSHA)
$5.48
$-0.12
(-2.14%)
As on 08-Sep-2026 16:24EDT
Market cap
$1,825 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
4.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.6
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
325,833,545
5 Years Aggregate
CFO
$-309.04 Mln
EBITDA
$-429.99 Mln
Net Profit
$-500.72 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Taysha Gene Therapies Inc (TSHA)
| -0.4 | -16.5 | -0.4 | 63.1 | 14.4 | -24.0 | -- |
|
BSE Sensex*
| -11.4 | -4.5 | 2.0 | -7.2 | 4.0 | 5.2 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Taysha Gene Therapies Inc (TSHA)
| 217.9 | -2.2 | -21.7 | -80.6 | -56.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Taysha Gene Therapies Inc (TSHA)
|
5.5 | 1,824.7 | 5.5 | -149.6 | -2,735.7 | -47.2 | -- | 4.7 |
| 85.1 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 75.4 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 57.7 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 108.3 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 351.3 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 116.5 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 534.2 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 590.9 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company... primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. Read more
-
CEO & Chairman
Mr. Sean P. Nolan
-
CEO & Chairman
Mr. Sean P. Nolan
-
Headquarters
Dallas, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Taysha Gene Therapies Inc (TSHA)
What is the current share price of Taysha Gene Therapies Inc (TSHA) Today?
The share price of Taysha Gene Therapies Inc (TSHA) is $5.48 (NASDAQ) as of 08-Sep-2026 16:24 EDT. Taysha Gene Therapies Inc (TSHA) has given a return of 14.4% in the last 3 years.
What is the current PB & PE ratio of Taysha Gene Therapies Inc (TSHA)?
Since, TTM earnings of Taysha Gene Therapies Inc (TSHA) is negative, P/E ratio is not available.
The P/B ratio of Taysha Gene Therapies Inc (TSHA) is 4.75 times as on 04-Sep-2026, a 11 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-16.13 |
7.12 |
2024 |
-3.97 |
4.96 |
2023 |
-2.97 |
4.42 |
2022 |
-0.77 |
134.28 |
2021 |
-2.54 |
4.65 |
What is the 52 Week High and Low of Taysha Gene Therapies Inc (TSHA)?
The 52-week high and low of Taysha Gene Therapies Inc (TSHA) are Rs 7.30 and Rs 2.72 as of 09-Sep-2026.
What is the market cap of Taysha Gene Therapies Inc (TSHA)?
Taysha Gene Therapies Inc (TSHA) has a market capitalisation of $ 1,825 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Taysha Gene Therapies Inc (TSHA)?
Before investing in Taysha Gene Therapies Inc (TSHA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.